| Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor AS Krall, S Xu, TG Graeber, D Braas, HR Christofk Nature communications 7 (1), 1-13, 2016 | 516 | 2016 |
| Small molecule inhibitors of CXCR4 B Debnath, S Xu, F Grande, A Garofalo, N Neamati Theranostics 3 (1), 47, 2013 | 313 | 2013 |
| Protein disulfide isomerase: a promising target for cancer therapy S Xu, S Sankar, N Neamati Drug discovery today 19 (3), 222-240, 2014 | 303 | 2014 |
| Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment S Xu, AN Butkevich, R Yamada, Y Zhou, B Debnath, R Duncan, E Zandi, ... Proceedings of the National Academy of Sciences 109 (40), 16348-16353, 2012 | 252 | 2012 |
| Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein B Debnath, S Xu, N Neamati Journal of medicinal chemistry 55 (15), 6645-6668, 2012 | 235 | 2012 |
| Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer S Xu, F Grande, A Garofalo, N Neamati Molecular cancer therapeutics 12 (6), 937-949, 2013 | 147 | 2013 |
| Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer R Li, SL Ong, LM Tran, Z Jing, B Liu, SJ Park, ZL Huang, TC Walser, ... Scientific reports 10 (1), 377, 2020 | 112 | 2020 |
| gp130: a promising drug target for cancer therapy S Xu, N Neamati Expert opinion on therapeutic targets 17 (11), 1303-1328, 2013 | 96 | 2013 |
| A tumor agnostic therapeutic strategy for hexokinase 1–null/hexokinase 2–positive cancers S Xu, HR Herschman Cancer research 79 (23), 5907-5914, 2019 | 95 | 2019 |
| Giant magnetoelastic effect enabled stretchable sensor for self-powered biomonitoring X Zhao, G Chen, Y Zhou, A Nashalian, J Xu, T Tat, Y Song, A Libanori, ... ACS nano 16 (4), 6013-6022, 2022 | 91 | 2022 |
| Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update M Millard, D Pathania, F Grande, S Xu, N Neamati Current pharmaceutical design 17 (6), 536-559, 2011 | 80 | 2011 |
| Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1, 6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties LF Zeng, Y Wang, R Kazemi, S Xu, ZL Xu, TW Sanchez, LM Yang, ... Journal of Medicinal Chemistry 55 (22), 9492-9509, 2012 | 66 | 2012 |
| Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients L Yang, X Yan, J Chen, Q Zhan, Y Hua, S Xu, Z Li, Z Wang, Y Dong, ... Proceedings of the National Academy of Sciences 118 (11), e2012228118, 2021 | 59 | 2021 |
| Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion IA Elliott, AM Dann, S Xu, SS Kim, ER Abt, W Kim, S Poddar, A Moore, ... Proceedings of the National Academy of Sciences 116 (14), 6842-6847, 2019 | 53 | 2019 |
| An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma S Xu, T Zhou, HM Doh, KR Trinh, A Catapang, JT Lee, D Braas, ... Cancer research 79 (10), 2748-2760, 2019 | 46 | 2019 |
| Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes S Xu, Y Liu, K Yang, H Wang, A Shergalis, A Kyani, A Bankhead III, ... Theranostics 9 (8), 2282, 2019 | 45 | 2019 |
| Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery R Yamada, MB Kostova, RK Anchoori, S Xu, N Neamati, S Khan Cancer biology & therapy 9 (3), 192-203, 2010 | 44 | 2010 |
| Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer S Xu, H Adisetiyo, S Tamura, F Grande, A Garofalo, P Roy-Burman, ... British journal of Cancer 113 (2), 242-251, 2015 | 43 | 2015 |
| Stabilization of MDA-7/IL-24 for colon cancer therapy S Xu, T Oshima, T Imada, M Masuda, B Debnath, F Grande, A Garofalo, ... Cancer letters 335 (2), 421-430, 2013 | 40 | 2013 |
| A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers S Xu, A Catapang, D Braas, L Stiles, HM Doh, JT Lee, TG Graeber, ... Cancer & metabolism 6, 1-17, 2018 | 34 | 2018 |
